A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of ER+, HER2- early-stage invasive breast cancer without evidence of distant metastasis - completed surgery - received at least 24 months but not more than 60 months of any endocrine therapy after treatment - may be limited with strenuous activity but able to walk and carry out work of a light or sedentary nature, e.g., light house work, office work

Exclusion Criteria:

- any evidence of metastatic disease - more than a 6 month consecutive gap in therapy during the course of prior adjuvant endocrine therapy - history of any other cancer - women who are pregnant, breastfeeding, or expecting to conceive or men expecting to father children

Conditions & Interventions

Conditions:
Cancer
Keywords:
Breast cancer, ER+, Hormone positive, hormone therapy

More Information

Description: Disruption of estrogen signaling by drugs called selective estrogen receptor degraders (SERDs) is one of the treatment options for patients with estrogen receptor positive (ER+) cancers. Imlunestrant is a SERD that disrupts estrogen signaling, and therefore should stop or slow down tumor growth in ER+ cancers. This study will help answer research questions about the safety of imlunestrant and any side effects, and how imlunestrant compares to standard-of-care endocrine therapy.
Study Contact: Kris DeBoer - kdeboer1@fairview.org
Principal Investigator: Kiran Lassi
IRB Number: STUDY00018436